Discontinuing immunotherapy in satble disease – pro
Current approach to stable disease on immunotherapy is to continue therapy until a true progression occurs. In many cases, stopping therapy will not affect stable disease in either direction, but this had not been well-studies and would not be clinically recommended. Marron et al reflect this reality in concluding: ” Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI.”.
Marron TU, Ryan AE, Reddy SM, Kaczanowska S, Younis RH, et al, Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer. 2021 Mar; 9(3): e001901.
Asher N, Israeli-Weller N, Shapira-Frommer R, Ben-Betzalel G, Schachter J, Meirson T, Markel G. Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience. Cancers (Basel). 2021 Jun 20;13(12): 3074.